Navigating FDA Section 361 Cell Product Compliance

Navigating FDA Section 361 compliance for human cell products requires medical practices to verify that all cellular and tissue-based products (HCT/Ps) meet strict regulatory criteria: minimal manipulation, homologous use, and a non-systemic primary mechanism of action. Under 21 CFR Part 1271, Section 361 products do not require premarket approval or Biologics License Applications (BLA), provided the processing and clinical application adhere strictly to FDA guidelines and suppliers maintain compliant Current Good Tissue Practice (cGTP) facilities. Practice managers and clinicians must establish rigorous vendor verification, temperature-controlled chain of custody, and meticulous patient record-keeping to mitigate legal and operational risk.

Understanding FDA Section 361 vs. Section 351 HCT/P Classification

The regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the United States falls under Title 21 of the Code of Federal Regulations (21 CFR Part 1271). The Food and Drug Administration (FDA) categorizes these products under two distinct sections of the Public Health Service (PHS) Act: Section 361 and Section 351.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. Because these products meet specific low-risk criteria, they do not require clinical trials, Investigational New Drug (IND) applications, or BLA premarket approval before clinical use. To qualify under Section 361, an HCT/P must satisfy four specific criteria defined in 21 CFR 1271.10(a):

1. Minimal Manipulation: Processing must not alter the original relevant biological characteristics of structural tissue, or the utility of non-structural cellular tissue.
2. Homologous Use: The tissue must perform the same basic function or functions in the recipient as it did in the donor.
3. No Combination: The HCT/P must not be combined with another drug or device, except for water, crystalloids, or specific sterilizing, preserving, or storage agents.
4. Non-Systemic Effect: The product must not depend on the metabolic activity of living cells for its primary function, unless it is for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

If an HCT/P fails to meet even one of these criteria—such as a structural tissue processed in a manner that changes its physical characteristics or applied for a non-homologous purpose—it is classified as a Section 351 drug, device, or biological product. Section 351 products require full premarket approval, extensive clinical trial validation, and strict drug manufacturing oversight. Practicing clinicians and healthcare administrators evaluating biologics must maintain clarity on these boundaries to ensure their clinical offerings remain fully compliant.

Operational vs. Clinical Perspectives on 361 Compliance

Navigating regulatory compliance requires seamless alignment between administrative procurement teams and treating physicians. Each role carries specific responsibilities in maintaining Section 361 integrity across the clinical lifecycle.

Operational and Administrative Responsibilities

Practice managers and procurement administrators bear primary responsibility for vendor qualification, inventory integrity, and administrative record retention. Key operational focus areas include:

• Vendor Verification: Confirming that all tissue suppliers maintain an active FDA Tissue Establishment Registration (Form FDA 3488) and provide transparent documentation of cGTP compliance.
• Cold-Chain Management: Ensuring cryopreservation storage units maintain verified temperature logs, with calibrated monitoring devices and emergency backup systems.
• Inventory Lot Tracking: Maintaining logs that map every tissue unit received, stored, and utilized back to its specific donor lot number and expiration date.
• Risk Mitigation: Conducting quarterly compliance reviews to ensure all incoming tissue documentation matches current clinical service lines.

Clinical and Provider Responsibilities

Treating physicians and clinical staff hold direct responsibility for diagnostic justification, patient communication, and proper administration techniques. Key clinical focus areas include:

• Homologous Use Determination: Documenting clear medical rationale showing that the tissue graft is being utilized to replace, repair, or cushion analogous anatomical structures.
• Informed Consent Protocols: Ensuring patient consent forms accurately describe the nature of the allogeneic or autologous tissue product, its regulatory framework, and the anticipated clinical objective without making unapproved drug claims.
• Aseptic Administration: Adhering strictly to clinical protocols during product handling, thawing, and application to preserve graft viability and patient safety.
• Adverse Event Logging: Establishing clinical protocols to immediately document, isolate, and report any suspected adverse reactions to both the vendor and relevant regulatory authorities.

Clinicians delivering therapies across specialized fields—such as orthopedic doctors and sports medicine providers—must ensure their diagnostic notes explicitly support homologous tissue replacement.

Vendor Evaluation Checklist for 361 Biologics Procurement

To protect practice operations and ensure patient safety, practice administrators should evaluate prospective tissue banks and distributors against a standardized compliance checklist before finalizing procurement agreements:

• Active FDA Registration: Verify current listing on the FDA Establishment Registration Search database.
• cGTP Quality Management Systems: Request proof of recent quality audits, cleanroom environmental monitoring protocols, and standard operating procedures.
• Donor Screening and Testing: Confirm that donor eligibility determinations comply with 21 CFR 1271 Subpart C, utilizing CLIA-certified laboratories for communicable disease testing.
• Validated Processing Procedures: Ensure tissue processing methods maintain minimal manipulation standards without chemical cross-linking or enzymatic structural degradation.
• Chain of Custody Tracking: Require temperature-validated shipping containers with continuous temperature data loggers included in every delivery.
• Clear Intended Use Labeling: Review product packaging and technical data sheets to confirm the manufacturer makes no unapproved systemic, metabolic, or disease-curing claims.
• Certificate of Analysis (CoA): Ensure every unit shipped includes a lot-specific CoA detailing sterility testing, donor clearing, and structural verification.

Integrating Compliance Protocols into Practice Workflows

Establishing compliant daily operations requires embedding regulatory verification directly into existing practice workflows. When tissue products arrive at a facility, receiving staff must inspect shipping containers for seal integrity and review the included temperature indicators before logging the lot number into the practice inventory management system.

Prior to clinical application, clinical staff should verify that the donor identification number on the vial or package matches the patient chart documentation exactly. EHR templates should include designated fields for tissue manufacturer, product name, lot number, expiration date, anatomical application site, and the specific clinical rationale supporting homologous use. Maintaining these structured entries simplifies internal audits and ensures complete transparency should regulatory queries arise.

Medical practices expanding their regenerative service offerings should also review patient educational materials, website copy, and marketing collateral. Describing Section 361 tissue products as systemic cures or unapproved cellular drugs introduces significant compliance exposure. Aligning external communication with accepted homologous tissue definitions safeguards practice reputation while educating patients accurately.

What This Means for Your Practice

Maintaining rigorous Section 361 compliance protects your practice from regulatory intervention while reinforcing clinical excellence. Practice leaders should take the following concrete actions:

1. Audit Current Tissue Inventory: Review all HCT/P products currently stocked in your practice to verify active FDA tissue establishment registrations and complete Certificates of Analysis for every lot.
2. Update EHR Documentation Templates: Modify procedural notes to capture donor lot numbers, expiration dates, precise application sites, and clinical descriptions of homologous intent.
3. Review Clinical Marketing Copy: Ensure practice websites, social media content, and patient brochures describe tissue grafts strictly in terms of homologous structural support.
4. Standardize Vendor Intake: Implement a formal vendor qualification process that re-verifies supplier cGTP status and registration annually.

Maintaining Compliance Confidence

Navigating cellular regulatory frameworks requires ongoing vigilance, robust operational systems, and reliable manufacturing partners. By establishing clear standard operating procedures for vendor qualification, inventory logging, and clinical documentation, practice managers and clinicians can confidently offer advanced tissue technologies within a secure compliance environment.

For additional insights on regulatory compliance, vendor documentation, or integrating high-quality biologics into your clinical workflow, review our comprehensive FAQ section or contact Dallas Regenerative Solutions to speak with a specialist.